The FDA Has Blessed Its First Medical Device to Tackle Opioid Withdrawal
People weaning themselves from painkillers may soon get a helping hand via a zap in the brain. The FDA says the snappy-sounding Neuro-Stim System Bridge, which costs between $600 and $800, can now be marketed as a way to treat opioid withdrawal.
It’s a seemingly simple device, which attaches to the skin behind the ear and uses a chip to stimulate part of the brain that usually processes pain information such as that created by withdrawal. While it’s been used in clinics to treat withdrawal in the past, until now it was approved by the FDA only for treatment of acute and chronic pain—not symptoms related to halting opioid consumption.
As Stat points out, the evidence supporting the device’s efficacy is slim: the FDA cites just a single study including 73 patients. But that series of experiments did show that 88 percent of them “successfully transitioned” away from opioids after using the device for five days. And at any rate, it’s a start against an overpowering scourge.
More solutions may be forthcoming. As we’ve reported, devices like the Bridge are just one of a series of promising approaches to beating addictive drugs—and in the meantime, the quest for painkillers that aren’t addictive continues, too.
Keep Reading
Most Popular
Everyone in AI is talking about Manus. We put it to the test.
The new general AI agent from China had some system crashes and server overload—but it’s highly intuitive and shows real promise for the future of AI helpers.
The foundations of America’s prosperity are being dismantled
Federal scientists warn that Americans could feel the effects of the new administration's devastating cuts for decades to come.
AI reasoning models can cheat to win chess games
These newer models appear more likely to indulge in rule-bending behaviors than previous generations—and there’s no way to stop them.
OpenAI has released its first research into how using ChatGPT affects people’s emotional well-being
We’re starting to get a better sense of how chatbots are affecting us—but there’s still a lot we don’t know.
Stay connected
Get the latest updates from
MIT Technology Review
Discover special offers, top stories, upcoming events, and more.